Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2236-2244

  Pitot, Henry C ^a,c   Goldberg, Richard M ^a   Reid, Joel M ^a   Sloan, Jeff A ^a   Skaff, Pam Atherton ^a   Erlichman, Charles ^a   Rubin, Joseph ^a   Burch, Patrick A ^a   Adjei, Alex A ^a   Alberts, Steven A ^a   Schaaf, Larry J ^b   Elfring, Gary ^b   Miller, Langdon L ^b  

^a MAYO CLINIC   (United States)

^b PFIZER INC   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ATROPINE; ATROPINE PLUS DIPHENOXYLATE; DEXAMETHASONE; DRUG METABOLITE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; IRINOTECAN; KAOLIN PECTIN; LOPERAMIDE; ONDANSETRON;

ABDOMINAL CRAMP; ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

ADJUVANTS, ANESTHESIA; ADULT; AGED; AGED, 80 AND OVER; ANTIDIARRHEALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; ATROPINE; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEXAMETHASONE; DIGESTIVE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GALLBLADDER NEOPLASMS; GLUCURONATES; HUMANS; LOPERAMIDE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TIME FACTORS;

EID: 0034047312     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Slichenmeyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
2. Pommier, Y., Tanizawa, A., and Kohn, K. W. Mechanisms of topoisomerase I inhibition by anticancer drugs. In: L. F. Liu (ed.), Advances in Pharmacology, pp. 73-92. New York: Academic Press, 1994.
3. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
4. Kunimoto, T., Nitta, K., Tanaka, T., Uehera, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47: 5944-5947, 1987.
5. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., and Ogawa, N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol., 11: 909-913, 1993.
6. Rothenberg, M. L., Kuhn, J. G., Burris, H. A., III, Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., Rodriguez, G. I., Rock, M. K., and Von Hoff, D. D. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol., 11: 2194-2204, 1993.
7. Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T. L., Rock, M. K., and Donehower, R. C. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a 90-minute infusion every 3 weeks. Cancer Res., 54: 427-436, 1994.
8. Abigerges, D., Chabot, G. G., Armand, J. P., Herait, P., Gouyette, A., and Gandia, D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol., 13: 210-221, 1995.
9. Catimel, G., Chabot, G. G., Guastalla, J. P., Dumortier, A., Cote, C., Engel, C., Gouyette, A., Mathieu-Boue, A., Mahjoubi, M., and Clavel, M. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann. Oncol., 6: 133-140, 1995.
10. De Forni, M., Bugat, R., Chabot, G. G., Culine, S., Extra, J. M., Gouyette, A., Madelaine, I., Marty, M. E., and Mathieu-Boue, A. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients. Cancer Res., 54: 4347-4354, 1994.
11. Merrouche, Y., Extra, J. M., Abigerges, D., Bugat, R., Catimel, G., Suc, E., Marty, M., Herait, P., Mahjoubi, M., and Armand, J. P. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. J. Clin. Oncol., 15: 1080-1086, 1997.
12. Saltz, L. B., Kanowitz, J., Kemeny, N. E., Schaaf, L., Spriggs, D., Staton, B. A., Berkery, R., Steger, C., Eng, M., Dietz, A., Locker, P. K., and Kelsen, D. P. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J. Clin. Oncol., 14: 2959-2967, 1996.
13. nd ed., pp. 409-417. New York: Marcel Dekker, 1982.
14. Sloan, J. A., Atherton Skaff, P., Reid, J., Pitot, H. C., Erlichman, C., and Schaaf, L. Limiting sampling models for CPT-11 pharmacokinetics. Clin. Pharmacol. Ther., 65: 197, 1999.
15. Gandia, D., Abigerges, D., Armand, J. P., Chabot, G., DaCosta, L., de Forni, M., Mathieu-Boue, A., and Herait, P. CPT-11 induced cholinergic effects in cancer patients. J. Clin. Oncol., 11: 196-197, 1993.
16. Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A., Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith, L. S., Eckhardt, S. G., Weiss, G. R., Elfring, G. L., Rinaldi, D. A., Schaaf, L. J., and Von Hoff, D. D. Phase II trial of irinotecan in patients with progressive of rapidly recurrent colorectal cancer. J. Clin. Oncol., 14: 1128-1135, 1996.
17. Pitot, H. C., Wender, D. B., O'Connell, M. J., Schroeder, G., Goldberg, R. M., Rubin, J., Malliard, J. A., Knost, J. A., Ghosh, C., Kirschling, R. J., Levitt, R., and Windschitl, H. E. A Phase II trial of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma. J. Clin. Oncol., 15: 2910-2919, 1997.
18. Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., Bonneterre, J., Adenis, A., Seitz, J. F., Ganem, G., Namer, M., Conroy, T., Negrier, S., Merrouche, Y., Burki, F., Mousseau, M., Herait, P., and Mahjoubi, M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pre-treated with fluorouracil-based chemotherapy. J. Clin. Oncol., 15: 251-260, 1997.
19. 2 irinotecan (CPT-11) given every 2 weeks. Proc. Am. Soc. Clin. Oncol., 16: 268a, 1997.
20. Von Hoff, D. D., Rothenberg, M. L., Pilot, H. C., Elfring, G. L., Mohrland, J. S., Schaaf, L. J., Neff, L. L., Locker, P. K., Gibson, R. E., and Miller, L. L. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA-reviewed pivotal United States clinical trials. Proc. Am. Soc. Clin. Oncol., 16: 228a, 1997.
21. Pazdur, R., Zinner, R., Rothenberg, M. L., Von Hoff, D. D., Hainsworth, J. D., Blanke, C. D., Cox, J. V., Elfring, G. L., Wolf, D. L., Mohrland, J. S., Schaaf, L. J., and Petit, R. G. Age as a risk factor in irinotecan (CPT-11) treatment of 5-FU refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol., 16: 260a, 1997.
22. Wasserman, E., Myara, A., Paumier, D., Herait, P., Awad, L., Misset, J. L., and Cvitkovic, E. Baseline bilirubin (BIL) and its transient early increase predicts likelihood of severe neutropenia and diarrhea in CPT-11-based chemotherapy. Proc. Am. Soc. Clin. Oncol., 16: 219, 1997.
23. Slatter, J. G., Su, P., Sams, J. P., Schaaf, L. J., and Wienkers, L. C. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos., 25: 1157-1164, 1997.
24. Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K., and Kamataki, T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol., 9: 845-847, 1998.
25. Sasaki, Y., Yoshida, Y., Sudoh, K., Hakusui, H., Fujii, H., Otitsu, T., Wakita, H., Igarashi, T., and Itoh, K. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn. J. Cancer Res., 86: 111-116, 1995.
26. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
27. Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., de Forni, M., Extra, J. M., Mahjoubi, M., Herait, P., Armand, J. P., and Bugat, R. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during Phase I trials. Ann. Oncol., 6: 141-151, 1995.
28. Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., and Cvitkovic, E. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann. Oncol., 8: 1049-1051, 1997.
29. Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., and Ratain, M. J. Genetic predisposition to the metabolism of irinotecan (CPT-11). J. Clin. Invest., 101: 847-854, 1998.
30. Cunningham, D., Pyrhonen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., Jacques, C., and Herait, P. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352: 1413-1418, 1998.
31. Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., Awad, L., Herait, P., and Jacques, C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352: 1407-1412, 1998.
32. Fonseca, R., Goldberg, R. M., Erlichman, C., Sloan, J. A., Kaufmann, S. H., and Miller, L. L. Phase I study of the combination of CPT-11/5-FU and leucovorin (LV). Proc. Am. Soc. Clin. Oncol., 17: 203a, 1998.
33. Mullany, S., Svingen, P. A., Kaufman, S. H., and Erlichman, C. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother. Pharmacol., 42: 391-399, 1998.